<DOC>
	<DOCNO>NCT00112723</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose flavopiridol see well work treat patient lymphoma multiple myeloma . Drugs use chemotherapy , flavopiridol , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Flavopiridol Treating Patients With Relapsed Refractory Lymphoma Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine disease-specific dose-limiting toxicity maximum tolerate dose flavopiridol patient relapse refractory lymphoma multiple myeloma . II . Determine complete partial response rate patient select non-Hodgkin 's lymphoma ( e.g. , indolent B-cell , mantle cell , intermediate grade B-cell , T/NK-cell ) , Hodgkin 's lymphoma , multiple myeloma treat drug . III . Determine qualitative quantitative toxic effect drug , term organ specificity , time course , predictability , reversibility patient . IV . Determine subsets lymphoid/plasma cell malignancy suitable large phase II study design evaluate efficacy toxicity drug patient . SECONDARY OBJECTIVES : I . Determine pharmacokinetics drug patient . II . Determine effect drug innate immunity ( include T- , B- , NK-cell subset ) quantitative immunoglobulin level patient . III . Determine whether acute infusion toxicity ( e.g. , fever , hypotension , tumor pain , dyspnea ) observe flavopiridol treatment schedule relate cytokine-release syndrome patient . IV . Determine whether drug induces response ( independent p53 mutational status ) patient . OUTLINE : This phase I , dose-escalation study follow multicenter , phase II , pilot study . Patients enrol phase II portion study stratify accord diagnosis . PHASE I : Patients receive flavopiridol IV 4½ hour day 1 , 8 , 15 , 22 . Treatment repeat every 6 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PHASE II : Patients receive flavopiridol* phase I MTD determine phase I . NOTE : The phase II treatment dose schedule hairy cell leukemia patient adapt developed previous phase II study flavopiridol treatment chronic lymphocytic leukemia . After completion study therapy , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Diagnosis 1 follow hematologic malignancy : Hodgkin 's lymphoma NonHodgkin 's lymphoma ( NHL ) Multiple myeloma Patients phase II portion study enrol 1 follow stratum accord diagnosis* Stratum 1 : Indolent Bcell NHL ( nonHodgkin 's lymphoma ) , follicle center Bcell NHL ( grade 1 , 2 , 3 ) , marginal zone lymphoma , Waldenstrom 's macroglobulinemia , small lymphocytic lymphoma ( without blood lymphocytosis point disease process ) Must progressive lymphadenopathy , worsen cytopenia , progressive symptom attribute lymphoma Must require therapy , determine progressive anemia , thrombocytopenia , symptom ( e.g. , fever , night sweat , weight loss , fatigue ) , progressive lymphadenopathy cause discomfort Received ≥ 2 prior therapy , include rituximab Stratum 1a : Hairy cell leukemia Must require therapy , determine progressive cytopenia symptom ( fever , night sweat , weight loss , fatigue ) Must receive ≥ 2 therapy Stratum 2 : Mantle cell lymphoma , determine presence cyclin D1 staining OR ( 11 ; 14 ) Stratum 3 : Intermediate grade Bcell NHL , include diffuse large Bcell NHL Tcell rich Bcell NHL Diffuse large Bcell NHL arise indolent NHL ( i.e. , transform lymphoma ) allow Ineligible potentially curative autologous stem cell transplantation Stratum 4 : Tcell natural killercell NHL , include anaplastic large cell lymphoma peripheral Tcell NHL Primary cutaneous lymphoma Sezary syndrome allow provide criterion measurable disease meet Received ≥ 1 prior systemic therapy Stratum 5 : Hodgkin 's lymphoma Any follow subtypes allow : Nodular sclerosing Mixed cellularity Lymphocyte predominant Lymphocyte deplete Ineligible potentially curative autologous stem cell transplantation Stratum 6 : Progressive stage I stage II IIIA multiple myeloma meeting ≥ 1 major 1 minor criterion OR ≥ 3 minor criterion follow : Major criterion Plasmacytoma tissue biopsy Bone marrow plasmacytosis ≥ 30 % marrow cellularity Monoclonal paraprotein ≥ 3,500 mg/dL ( IgG ) , ≥ 2,000 mg/dL ( IgA ) , OR monoclonal protein ( BenceJones protein ) ≥ 1,000 mg 24hour urine collection Minor criterion Bone marrow plasmacytosis 1029 % marrow cellularity Monoclonal paraprotein &lt; 3,500 mg/dL ( IgG ) &lt; 2,000 mg/dL ( IgA ) Lytic bone lesion xray CT scan Decrease normal IgM ( &lt; 50 mg/dL ) , IgA ( &lt; 100 mg/dL ) , IgG ( &lt; 600 mg/dL ) Relapsed refractory disease Measurable disease , define 1 following : At least 1 node &gt; 2 cm CT scan Measurable disease lymphoid structure ( i.e. , spleen ) CT scan Bone marrow involvement ( &gt; 20 % marrow cellularity ) Patients multiple myeloma must detectable serum urinary paraprotein Patients cutaneous subcutaneous disease ( i.e. , measurable lymph node bone marrow disease ) eligible extent rash skin involvement OR size nodule measurable Must receive ≥ 1 prior therapy Steroids alone consider prior therapy patient NHL Hodgkin 's lymphoma Highdose dexamethasone consider 1 prior therapy patient multiple myeloma No standard effective therapy exist No HIVassociated lymphoma No nonsecretory multiple myeloma Performance status ECOG ( Eastern Cooperative Oncology Group ) 02 No concurrent hormonal therapy except steroid new adrenal failure hormone administer nondiseaserelated condition ( e.g. , insulin diabetes ) Hemoglobin ≥ 9.0 g/dL* Absolute neutrophil count ≥ 1,500/mm^3* Platelet count ≥ 50,000/mm^3* AST ( aspartate aminotransferase ) ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ 2 time ULN No major renal dysfunction would preclude study compliance participation Phase I : Creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 70 mL/min Phase II : Creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 50 mL/min No cardiac vascular dysfunction would preclude central venous access , vigorous hydration , hemodialysis No major cardiac dysfunction would preclude study compliance participation No major pulmonary dysfunction would preclude study compliance participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No chronic gastrointestinal disease ( e.g. , Crohn 's disease , ulcerative colitis , short gut syndrome ) would preclude study compliance participation No major organ system ( include neurological psychiatric ) dysfunction would preclude study compliance participation Prior radiotherapy , include radioimmunotherapy , allow No concurrent radiotherapy Prior idiotype vaccination stem cell transplantation allow More 6 week since prior mitomycin nitrosoureas No concurrent chemotherapy More 4 week since prior therapy Prior systemic steroid allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>